CanSino Biologics Statistics

Total Valuation

CanSino Biologics has a market cap or net worth of HKD 11.32 billion. The enterprise value is 10.01 billion.

Market Cap	11.32B
Enterprise Value	10.01B

Important Dates

The next estimated earnings date is Wednesday, March 26, 2025.

Earnings Date	Mar 26, 2025
Ex-Dividend Date	n/a

Share Statistics

CanSino Biologics has 247.04 million shares outstanding. The number of shares has decreased by -0.03% in one year.

Current Share Class	n/a
Shares Outstanding	247.04M
Shares Change (YoY)	-0.03%
Shares Change (QoQ)	-1.11%
Owned by Insiders (%)	28.52%
Owned by Institutions (%)	9.59%
Float	168.80M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.14
PB Ratio	1.35
P/TBV Ratio	2.07
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-12.55
EV / Sales	12.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.66

Financial Position

The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.42.

Current Ratio	2.47
Quick Ratio	2.24
Debt / Equity	0.42
Debt / EBITDA	n/a
Debt / FCF	-2.25
Interest Coverage	-17.00

Financial Efficiency

Return on equity (ROE) is -13.62% and return on invested capital (ROIC) is -8.99%.

Return on Equity (ROE)	-13.62%
Return on Assets (ROA)	-7.92%
Return on Capital (ROIC)	-8.99%
Revenue Per Employee	554,947
Profits Per Employee	-533,879
Employee Count	1,494
Asset Turnover	0.09
Inventory Turnover	2.03

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +37.61% in the last 52 weeks. The beta is 0.52, so CanSino Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	+37.61%
50-Day Moving Average	29.75
200-Day Moving Average	22.47
Relative Strength Index (RSI)	50.98
Average Volume (20 Days)	1,063,945

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CanSino Biologics had revenue of HKD 829.09 million and -797.62 million in losses. Loss per share was -3.23.

Revenue	829.09M
Gross Profit	-28.65M
Operating Income	-1.24B
Pretax Income	-829.75M
Net Income	-797.62M
EBITDA	-919.04M
EBIT	-1.24B
Loss Per Share	-3.23

Full Income Statement

Balance Sheet

The company has 3.64 billion in cash and 2.33 billion in debt, giving a net cash position of 1.31 billion or 5.29 per share.

Cash & Cash Equivalents	3.64B
Total Debt	2.33B
Net Cash	1.31B
Net Cash Per Share	5.29
Equity (Book Value)	5.61B
Book Value Per Share	22.79
Working Capital	2.88B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -494.74 million and capital expenditures -541.89 million, giving a free cash flow of -1.04 billion.

Operating Cash Flow	-494.74M
Capital Expenditures	-541.89M
Free Cash Flow	-1.04B
FCF Per Share	-4.20

Full Cash Flow Statement

Margins

Gross margin is -3.46%, with operating and profit margins of -149.00% and -96.20%.

Gross Margin	-3.46%
Operating Margin	-149.00%
Pretax Margin	-100.08%
Profit Margin	-96.20%
EBITDA Margin	-110.85%
EBIT Margin	-149.00%
FCF Margin	n/a

Dividends & Yields

CanSino Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.03%
Shareholder Yield	0.03%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CanSino Biologics has an Altman Z-Score of 1.57. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.57
Piotroski F-Score	n/a